Clinical study
Frequency of diabetic ketoacidosis and hypoglycemic coma during treatment with continuous subcutaneous insulin infusion. Audit of medical care

https://doi.org/10.1016/0002-9343(85)90518-2Get rights and content

Abstract

The frequency of diabetic ketoacidosis and hypoglycemic coma in a large series of patients with insulin-dependent diabetes treated by long-term continuous subcutaneous insulin infusion was compared with the frequency of these events in a matched group of patients treated by conventional insulin injections at the same hospital over the same period of time. Ketoacidosis and hypoglycemic coma occurred no more frequently in continuous subcutaneous insulin infusion-treated patients. Therefore, intensified insulin therapy achieved by continuous subcutaneous insulin infusion does not appear to be associated with a greater risk of ketoacidosis or hypoglycemic coma than does conventional insulin therapy.

References (49)

  • R Miller

    Diabetic ketoacidosis during treatment with a portable insulin pump

    J Tenn Med Assoc

    (1982)
  • V Fishman et al.

    Practical problems with insulin pumps (letter)

    N Engl J Med

    (1982)
  • JC Shipp

    Practical problems with insulin pumps

    N Engl J Med

    (1982)
  • DF Gardner

    More vigilance is needed during pregnancy

    Diabetes Care

    (1982)
  • AJM Boulton et al.

    Diabetic ketoacidosis associated with outpatient treatment using continuous subcutaneous insulin infusion

    Postgrad Med J

    (1983)
  • DS Schade et al.

    Intensive insulin therapy

    (1983)
  • DR Lock et al.

    Hypoglycemic coma associated with subcutaneous insulin infusion by portable pump

    Diabetes Care

    (1981)
  • W Berger et al.

    Hypoglycemic coma due to use of an improper battery in a commonly used insulin pump (letter)

    Diabetes Care

    (1982)
  • AC Giacomet

    Hypoglycemic coma associated with CSII

    Diabetes Care

    (1983)
  • Centers for Disease Control

    Deaths among patients using continuous subcutaneous insulin infusion pumps-United States

    Morbid Mortal Weekly Rep

    (1982)
    Centers for Disease Control

    Deaths among patients using continuous subcutaneous insulin infusion pumps-United States

    Morbid Mortal Weekly Rep

    (1982)
  • SM Teutsch et al.

    Mortality among diabetic patients using continuous subcutaneous insulin-infusion pumps

    N Engl J Med

    (1984)
  • WMG Tunbridge

    Factors contributing to deaths of diabetics under fifty years of age

    Lancet

    (1981)
  • JC Pickup et al.

    Clinical features of brittle diabetic patients unresponsive to optimised subcutaneous insulin therapy (continuous subcutaneous insulin infusion)

    Diabetes Care

    (1983)
  • JC Pickup

    ABC of diabetes

  • Cited by (69)

    • Novel function of transthyretin in pancreatic alpha cells

      2012, FEBS Letters
      Citation Excerpt :

      Thus, the primary role of glucagon is correcting hypoglycemia caused by malnutrition, fasting, and treatment of diabetes to achieve normoglycemia [6–9]. Insulin treatment in diabetes, especially type 1 diabetes, greatly increases the risk of hypoglycemia, with effects on a number of organs including brain, and causes critical systemic symptoms such as hypoglycemic coma [10–12]. In addition, an absent glucagon response plays a prominent role in a failure to correct hypoglycemia induced by insulin and may exacerbate critical systemic symptoms [8].

    • Therapy in APS: Criteria and fundamentals for the utilization of insulin pump

      2009, FMC Formacion Medica Continuada en Atencion Primaria
    • Use of New Technologies for Monitoring and Treating Diabetes in Pregnancy

      2007, Obstetrics and Gynecology Clinics of North America
      Citation Excerpt :

      A few early studies indicated a high rate of ketoacidosis with CSII [39,40]. But as patients and caregivers became more experienced with the technique, the frequency of ketoacidosis decreased [41]. Several remediable factors increased the likelihood of ketoacidosis during the first experiences with CSII, including physician inexperience (poor choice of infusion rates, poor instructions to patients, and so forth), the use of unbuffered insulin (which can cause cannula blockage), cannula dislodgment or leakage, and unsuitable patients (poorly compliant).

    View all citing articles on Scopus
    1

    Dr. Bending was supported by Nordisk Gentofte.

    View full text